(Alliance News) - Hutchison China MediTech Ltd said Tuesday it has started its phase 1/1b study of small molecule inhibitor HMPL-689 in patients with advanced relapsed or refractory in the firm at Read More
(Alliance News) - Hutchison China Meditech Ltd on Friday said it has begun a phase 1 study of HMPL-523 as a treatment for immune thrombocytopenia in China, dosing the first patient on Monday last Read More
(Alliance News) - Hutchison China MediTech Ltd on Tuesday said its loss widened in the first half of the year due to expenses, while it has reduced guidance on expenses and cash flow.Shares Read More
(Alliance News) - Hutchison China Meditech Ltd on Wednesday said Prudential PLC held a 5.1% stake in the China-focused drug company.Following a deal on Friday last week, Prudential held in Read More
(Alliance News) - China-focused drug developer and distributor Hutchison China Meditech PLC said Friday the pricing of a secondary offer of its Nasdaq-listed shares has been fixed at USD24.00 also Read More
LONDON (Alliance News) - Hutchison China Meditech Ltd on Wednesday said its shareholders have approved a subdivision of shares at its extraordinary general meeting.The pharmaceutical that a Read More
LONDON (Alliance News) - Gama Aviation PLC on Wednesday said it has selected the managing director of major shareholder Hutchison Whampoa China Ltd as its new chair.Shares in business firm Read More
LONDON (Alliance News) - Biopharmaceutical firm Hutchison China MediTech Ltd on Friday said it has begun a study of cancer drug surufatinib in patients with advanced biliary tract biliary tract by Read More
LONDON (Alliance News) - Hutchison China Meditech Ltd on Monday said its loss widened in 2018 as sales decreased following an implementation of new government policy in China.The company to Read More
LONDON (Alliance News) - Hutchison China Meditech Ltd on Monday said it launched fruquintinib capsules Elunate with the initiation of product sales in China.Elunate is used for the of with Read More
